Abstracts tagged "Mouse model"

Abstract Number: 2316 • 2013 ACR/ARHP Annual Meeting
Anti-Human TNF-Alpha Domain Antibody Construct, CEP-37247/Placulumab, Is As Efficacious As Other Leading TNF-Alpha-Blockade Therapies in a Humanized Mouse Model of Rheumatoid Arthritis
Matthew M. Seavey¹, Linglong Zou², Adam Clarke³, Anthony G. Doyle³, Roberta Weiss⁴, Aric Orbach⁵, Brad McIntyre⁶ and Merav Bassan⁷, ¹Nonclinical Development, Pharmacology, Teva Pharmaceuticals, Inc., West Chester, PA, ²GB&T, Teva Biopharmaceuticals, Rockville, MD, ³Discovery Biologics, Teva Pharmaceuticals, Inc., Sydney, Australia, ⁴Clinical Development, Teva Pharmaceuticals, Inc., Frazer, PA, ⁵Nonclinical Development, Pharmacology, Teva Pharmaceuticals, Inc., Netanya, Israel, ⁶Formulation, Teva Pharmaceuticals, Inc., West Cheater, PA, ⁷Teva R&D - Innovative Project Leadership, Teva Pharmaceuticals, Inc., Netanya, Israel
Background/Purpose: The cytokine tumor necrosis factor (TNF)alpha is a potent pro-inflammatory mediator involved in several autoimmune diseases including rheumatic arthritis and for over a decade…
Abstract Number: 2232 • 2013 ACR/ARHP Annual Meeting
Neutralization of Angiopoietin-2 Enhances the Efficacy of Anti-Tumor Necrosis Factor-Alpha Treatment in a Mouse Model of Rheumatoid Arthritis by Decreasing Cellular Infiltration into the Joint and Protecting Bone
Brian Naiman, Sean Turman, William Iverson, Ronald Herbst, Tomas Mustelin and Jane Connor, Respiration, Inflammation and Autoimmunity, MedImmune, LLC, Gaithersburg, MD
Background/Purpose: It has recently been established that >75% of patients on methotrexate and a biologic do not achieve complete remission based on the new definition…
Abstract Number: 1284 • 2013 ACR/ARHP Annual Meeting
Nuclear Receptor 4A2 Is Differentially Expressed In Animal Models Of RA During Inflammation and Resolution
Jordan Everett¹, Fiona E. McCann², Andrew C. Palfreeman², Anita T. Shaw³, Ellen M. Gravallese⁴ and Kimberlee S. Mix¹, ¹Biological Sciences, Loyola University New Orleans, New Orleans, LA, ²NDORMS, The Kennedy Institute of Rheumatology, University of Oxford, London, United Kingdom, ³Division of Rheumatology, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ⁴Department of Medicine, Division of Rheumatology, UMass Memorial Medical Center, Worcester, MA
Background/Purpose: Nuclear receptor 4A2 (NR4A2 / nuclear receptor related 1 / Nurr1) is a constitutively active transcription factor with diverse roles in normal physiology and…
Abstract Number: 1251 • 2013 ACR/ARHP Annual Meeting
Collagen Antibodies Induce Pain-Like Behavior In Mice Without Signs Of Inflammation
Gustaf Wigerblad¹, Katalin Sandor¹, Kutty Selva Nandakumar², Rikard Holmdahl³ and Camilla Svensson¹, ¹Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, ²Department of Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden, ³Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Collagen Antibody Induced Arthritis (CAIA) is a mouse model of rheumatoid arthritis (RA). It is induced by injection of a cocktail of monoclonal antibodies…
Abstract Number: 918 • 2013 ACR/ARHP Annual Meeting
Regulatory B Cells Suppress Skin Inflammation in a Murine Model of Psoriasis
Koichi Yanaba¹ and Shinichi Sato², ¹Dermatology, The University of Tokyo, Tokyo, Japan, ²Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Psoriasis is a cutaneous disorder characterized by widespread erythematous plaques with adherent scales. Recent studies have revealed that both T helper (Th) 17 and…
Abstract Number: 771 • 2013 ACR/ARHP Annual Meeting
The S100A9 Inhibitor Paquinimod (ABR-215757) Reduces Synovial Activation, Osteophyte Formation and Cartilage Damage In Experimental Osteoarthritis
Rik Schelbergen¹, Arjen B. Blom¹, Tomas Leanderson², Helena Eriksson³, Wim B. van den Berg⁴ and Peter L.E.M. van Lent¹, ¹Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Immunology Group, Lund University, Lund, Sweden, ³BioScience, Active Biotech AB, Lund, Sweden, ⁴Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Synovial activation is present in a large subset of osteoarthritis (OA) patients and it is thought to play an important role in the development…
Abstract Number: 46 • 2013 ACR/ARHP Annual Meeting
Alarmins S100A8/A9 Regulate Osteophyte Formation In Experimental Osteoarthritis With High Synovial Activation
Rik Schelbergen¹, Arjen B. Blom¹, Wouter de Munter¹, Annet W. Sloetjes², Thomas Vogl³, Johannes Roth⁴, Wim B. van den Berg⁵ and Peter L.E.M. van Lent¹, ¹Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands, ³Institute of Immunology, University of Muenster, Muenster, Germany, ⁴Immunology, Institute of Immunology University of Muenster, Muenster, Germany, ⁵Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Osteophytes are cartilage capped, bony outgrowths that limit joint movement and originate from the periosteum or from ligaments during osteoarthritis (OA). There is increasing…
Abstract Number: 48 • 2013 ACR/ARHP Annual Meeting
The In Vivo Role Of Bone Specific EphB4 Receptor Overexpression In Osteoarthritic Synovial Membrane
Gladys Valverde-Franco¹, David Hum¹, Bertrand Lussier², Koichi Matsuo³, Jean-Pierre Pelletier¹, Mohit Kapoor¹ and Johanne Martel-Pelletier¹, ¹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ²Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, QC, Canada, ³Laboratory of Cell and Tissue Biology, School of Medicine, Keio University, Tokyo, Japan
Background/Purpose: Osteoarthritis (OA) is characterized by progressive destruction of all joint tissues including inflammation of the synovial membrane. The histological changes that occur in OA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].